CBLI: Summary for Cleveland BioLabs, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 1:13am EST - Canadian Markets open in 8 hours and 17 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Cleveland BioLabs, Inc. (CBLI)

On Feb 9: 3.85 USD

0.05 (1.28%)

MORE ON CBLI

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Cleveland BioLabs, Inc. (NCM:CBLI) Delayed quote data

Last Trade:	3.85 USD
Trade Time:	Feb 9
Change:	0.05 (1.28%)
Prev Close:	3.90
Open:	3.87
Bid:	2.95 x 100
Ask:	4.76 x 600
1y Target Est:	13.10

Day's Range:	3.75 - 4.00
52wk Range:	1.15 - 6.35
Volume:	24,360
Avg Vol (3m):	63,479.4
Market Cap:	77.49M
P/E (ttm):	N/A
EPS (ttm):	-1.81
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y

Add CBLI to Portfolio

Download Data

HEADLINES

•	CLEVELAND BIOLABS INC Files SEC form 8-K, Other Events
	EDGAR Online (Tue, Feb 2)

•	Cleveland BioLabs Granted European Patent for Radiation Protection Drug CBLB502
	Marketwire (Thu, Jan 28)

•	Cleveland BioLabs to Present at 12th Annual BIO CEO & Investor Conference
	Marketwire (Wed, Jan 27)

•	Buffalo researcher lands $1.7M grant
	at bizjournals.com (Thu, Jan 21)

•	Cleveland BioLabs Doses First Volunteers in Second Safety Study for CBLB502
	Marketwire (Tue, Jan 19)

•	Cleveland BioLabs to Respond to Department of Defense Request for Proposal for Radiation Countermeasure
	Marketwire (Tue, Jan 12)

•	Sunesis, Taser: Midday Volume Plays
	at TheStreet.com (Wed, Jan 6)

•	Cleveland BioLabs Receives First U.S. Patent for Radiation Protection Drug CBLB502
	Marketwire (Wed, Jan 6)

•	CLEVELAND BIOLABS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stateme
	EDGAR Online (Tue, Jan 5)

•	Cleveland BioLabs to Present at OneMedForum
	Marketwire (Tue, Jan 5)

More Headlines for CBLI...

ANALYST

EPS Est (next year) (Dec-07) :	N/A
EPS Est (in 2 years) (Dec-08) :	N/A
Avg Rec (current)*:	2.0
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

CLEVELAND BIOLABS, INC. engages in the discovery, development, and commercialization of products for cancer treatment and protection of normal tissues from radiation and toxins in the United States.

Full Company Profile

Add to Portfolio

Email to a Friend

•